Compare TTC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTC | AXSM |
|---|---|---|
| Founded | 1914 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tools/Hardware | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 9.0B |
| IPO Year | 1994 | 2015 |
| Metric | TTC | AXSM |
|---|---|---|
| Price | $94.15 | $164.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 17 |
| Target Price | $104.00 | ★ $210.65 |
| AVG Volume (30 Days) | ★ 976.5K | 481.9K |
| Earning Date | 03-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $2,618,650,000.00 | N/A |
| Revenue This Year | $6.11 | $58.18 |
| Revenue Next Year | $4.45 | $55.45 |
| P/E Ratio | $136.06 | ★ N/A |
| Revenue Growth | ★ 4.53 | N/A |
| 52 Week Low | $62.34 | $86.99 |
| 52 Week High | $105.19 | $191.50 |
| Indicator | TTC | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 50.39 |
| Support Level | $76.60 | $153.37 |
| Resistance Level | $102.32 | $169.11 |
| Average True Range (ATR) | 2.41 | 4.25 |
| MACD | -0.47 | 0.92 |
| Stochastic Oscillator | 22.78 | 72.17 |
The Toro Co designs, manufactures, markets, and sells professional turf maintenance equipment and services; turf and agricultural irrigation systems; landscaping equipment and lighting products; snow and ice management equipment; construction equipment; and residential yard and snow thrower products. The company operates through Professional and Residential segments, with the Professional segment serving commercial, agricultural, and construction customers and generating the majority of revenue, while the Residential segment focuses on homeowners. Its products are sold through distributors, dealers, retailers, rental centers, and direct channels, with the United States as its primary revenue-generating market.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.